Sign in

What researchers published on Lung cancer

162,321 papers, newest first.

Showing 20 of 5,530

  • Randomised trialDirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.Cancer communications (London, England)
  • Trial resultCombined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies.Cancer communications (London, England)
  • Randomised trialEffects of CT-guided Radiofrequency Versus Microwave Ablation on Pulmonary Function in Individuals with Pulmonary Tumors: A Prospective Multicenter Randomized Trial.Radiology. Imaging cancer
  • Randomised trialTransbronchial Cryobiopsy for the Diagnosis of Peripheral Pulmonary Lesions: A Prospective Randomized Controlled Study.Journal of visualized experiments : JoVE
  • Trial resultA CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial.Nature communications
  • Randomised trialThalidomide dose selection for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a multicenter, randomized phase II trial.Frontiers in immunology
  • Randomised trialEarly functional deterioration during first-line ICI-based therapy in advanced NSCLC: implications for supportive care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • Randomised trialAutomated Opportunistic Bone Mineral Density Assessment at Low-Dose CT Lung Cancer Screening: Incident Vertebral Fractures and Mortality.Radiology
  • Randomised trialRuzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.Lancet (London, England)
  • Randomised trialClosed Versus Open Vent Port Techniques and the Disconnection Technique for Optimizing Lung Collapse With Bronchial Blockers in Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial.The clinical respiratory journal
  • Trial resultEffect of Acupuncture for Loss of Appetite in Advanced Lung Cancer Undergoing Immunotherapy: Protocol of a Randomized Controlled Trial.Integrative cancer therapies
  • Trial resultEffects of multiple low-dose intranasal dexmedetomidine administration on postoperative pulmonary complications in elderly patients undergoing thoracoscopic radical resection of lung cancer: a single-center randomized controlled trial.Frontiers in pharmacology
  • Randomised trialFirmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.Cancer cell
  • Trial resultLazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.European journal of cancer (Oxford, England : 1990)
  • Randomised trialCamrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.Signal transduction and targeted therapy
  • Trial resultEfficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG).Frontiers in immunology
  • Trial resultCanakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.Nature communications
  • Randomised trialDexketoprofen Trometamol Plus Sufentanil for Analgesia After Thoracoscopic Radical Resection of Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.Drug design, development and therapy
  • Trial resultFarletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.Gynecologic oncology
  • Trial resultSUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.Future oncology (London, England)